A number of articles from Canadian authors
came out recently and demonstrate the wide scope of our interests
in Alzheimer’s disease (AD) & related disorders: Hsiung
et al gave an update on the ACCORD study, Rockwood et al introduce
the TOPS symptom checklist, Herrmann et al estimate the cost
of neuropsychiatric symptoms (see the Faxback section) and Smith
et al estimate the treatment effect size of memantine.
Outcomes of cognitively impaired
not demented at 2 years in the Canadian Cohort Study of Cognitive
Impairment and Related Dementias
(DEMENT GERIATR COGN DISORD 2006;22:413-420)
GING-YUEK R. HSIUNG,
ALAN DONALD,
JACOB GRAND,
SANDRA E. BLACK
ET AL,
various centres, caN
Specific symptomatic changes following
donepezil treatment of Alzheimer’s disease: a multi-centre,
primary care, open-label study
(INT J GERIATR PSYCHIATRY dx.doi.org/10.1002/gps.1675)
KENNETH ROCKWOOD,
SANDRA BLACK,
MARC-ANDRE BEDARD,
THANG TRAN,
ET AL,
various centres, can
Treatment effect size of memantine
therapy in Alzheimer disease and vascular dementia
(ALZHEIMER DIS ASSOC DISORD 2006;20:133-137)
MATTHEW SMITH, BASc,
JENNIE WELLS, MSc, MD,
MICHAEL BORRIE, MB, ChB
LONDON, ON
|
